6July - 2020TECH OUTLOOKEditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comAs the COVID-19 pandemic continues to wreak havoc, the world is in a race to find a treatment for the novel coronavirus. The pharmaceutical companies are at the forefront of this battle, researching for potential COVID-19 vaccines, diagnostic tools, and treatments. The crisis has brought in itself as a double-edged sword for the industry. On one hand, the industry is encountering global supply chain disruption and low productivity, while on the other, it needs grants and sanctions from the governments to bolster the manufacturing of raw materials and active pharmaceutical ingredients (API). However, the industry, boosted by innovation, is expected to pick up from where it was left off once the crisis settles down. Today, in the pharmaceutical industry, the increasing focus on customized care and technological advancements has shortened the product lifecycles and has boosted the development of new products, which require advanced analytical tests. Besides, the rising demand from the nutraceutical industry, the patent cliff, and the adoption of full-time equivalent (FTE) contracts have made outsourcing analytical services a preferred option for most of the pharma companies. Further, outsourcing allows companies to benefit from skilled professionals and expensive cutting-edge analytical equipment in the sector. In this edition of Pharma Tech Outlook, we bring you the story of some of the most successful analytical services companies that deliver the best outcomes for their clients. This edition also offers a combination of thought leadership from subject matter experts and exclusive insights from CIOs and CXOs. We hope this edition will provide you with the right assistance in choosing the best analytical service according to your requirements.Let us know your thoughts!In the Quest for Shorter Product LifecyclesCopyright © 2020 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.JULY - 06 - 2020, Vol 06 - Issue 13 (ISSN 2644-2787) Published by ValleyMedia, Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com *Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffEditor-in-ChiefStacey SmithVisualizerAsher BlakeEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul BarberSalesBrian Thomasbrian@pharmatechoutlook.comPhone: 510.556.2402sales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:Contact Us:Phone:510.556.2402, Fax:510-894-8405Jaxon JaseTECH OUTLOOKTECH OUTLOOK
< Page 5 | Page 7 >